O	0	6	Effect
O	7	9	of
O	10	12	an
B-intervention	13	22	essential
I-intervention	23	26	oil
I-intervention	27	34	mixture
O	35	37	on
B-condition	38	42	skin
I-condition	43	52	reactions
O	53	55	in
B-eligibility	56	61	women
I-eligibility	62	72	undergoing
I-eligibility	73	85	radiotherapy
I-eligibility	86	89	for
I-eligibility	90	96	breast
I-eligibility	97	103	cancer
O	103	104	:
O	105	106	a
O	107	112	pilot
O	113	118	study
O	118	119	.

O	120	124	This
O	125	130	pilot
O	131	136	study
O	137	145	compared
O	146	149	the
O	150	157	effects
O	158	160	of
O	161	163	an
O	164	173	essential
O	174	177	oil
O	178	185	mixture
O	186	192	versus
O	193	201	standard
O	202	206	care
O	207	209	on
O	210	214	skin
O	215	224	reactions
O	225	227	in
O	228	234	breast
O	235	241	cancer
O	242	250	patients
O	251	260	receiving
O	261	270	radiation
O	270	271	.

O	272	277	Using
O	278	280	an
O	281	293	experimental
O	294	300	design
O	300	301	,
B-total-participants	302	304	24
O	305	313	patients
O	314	318	were
O	319	329	randomized
O	330	332	to
B-control	333	341	standard
I-control	342	346	care
O	347	348	(
O	348	349	i
O	349	350	.
O	350	351	e
O	351	352	.
O	352	353	,
O	354	365	RadiaPlexRx
O	365	366	â„¢
O	367	375	ointment
O	375	376	)
O	377	379	or
O	380	382	an
O	383	392	essential
O	393	396	oil
O	397	404	mixture
O	404	405	.

O	406	414	Products
O	415	419	were
O	420	427	applied
O	428	437	topically
O	438	443	three
O	444	449	times
O	450	451	a
O	452	455	day
O	456	461	until
O	462	463	1
O	464	469	month
O	470	483	postradiation
O	483	484	.

O	485	491	Weekly
O	492	496	skin
O	497	508	assessments
O	509	513	were
O	514	522	recorded
O	523	526	and
O	527	532	women
O	533	542	completed
O	543	550	patient
O	551	563	satisfaction
O	564	567	and
O	568	575	quality
O	576	578	of
O	579	583	life
O	584	585	(
O	585	588	QOL
O	588	589	)
O	590	601	instruments
O	602	604	at
O	605	606	3
O	606	607	-
O	607	608	,
O	609	610	6
O	610	611	-
O	611	612	,
O	613	616	and
O	617	619	10
O	619	620	-
O	620	624	week
O	625	634	intervals
O	634	635	.

O	636	638	No
O	639	650	significant
O	651	662	differences
O	663	667	were
O	668	673	found
O	674	677	for
B-outcome	678	682	skin
O	682	683	,
B-outcome	684	687	QOL
O	687	688	,
O	689	691	or
B-outcome	692	699	patient
I-outcome	700	712	satisfaction
O	713	715	at
O	716	723	interim
O	724	726	or
O	727	733	follow
O	733	734	-
O	734	736	up
O	737	741	time
O	742	748	points
O	748	749	.

O	750	756	Effect
O	757	762	sizes
O	763	767	were
O	768	770	as
O	771	778	follows
O	778	779	:
B-outcome	780	784	skin
O	785	786	=
O	787	788	.
O	788	790	01
O	791	793	to
O	794	795	.
O	795	797	07
O	798	799	(
O	799	804	small
O	804	805	-
O	805	811	medium
O	812	818	effect
O	818	819	)
O	819	820	;
B-outcome	821	824	QOL
O	825	826	=
O	827	828	.
O	828	830	01
O	831	833	to
O	834	835	.
O	835	837	04
O	838	839	(
O	839	844	small
O	845	851	effect
O	851	852	)
O	852	853	;
B-outcome	854	861	patient
I-outcome	862	874	satisfaction
O	875	876	=
O	877	878	.
O	878	880	02
O	881	882	(
O	882	887	small
O	888	894	effect
O	894	895	)
O	895	896	.

O	897	900	The
O	901	910	essential
O	911	914	oil
O	915	922	mixture
O	923	926	did
O	927	930	not
O	931	938	provide
O	939	940	a
O	941	947	better
B-outcome	948	952	skin
I-outcome	953	963	protectant
I-outcome	964	970	effect
O	971	975	than
O	976	984	standard
O	985	989	care
O	989	990	.

O	991	996	These
O	997	1005	findings
O	1006	1013	suggest
O	1014	1017	the
O	1018	1027	essential
O	1028	1031	oil
O	1032	1039	mixture
O	1040	1042	is
O	1043	1053	equivalent
O	1054	1056	to
O	1057	1068	RadiaPlexRx
O	1068	1069	,
O	1070	1071	a
O	1072	1078	common
O	1079	1086	product
O	1087	1091	used
O	1092	1094	as
O	1095	1103	standard
O	1104	1108	care
O	1109	1114	since
O	1115	1117	it
O	1118	1121	has
O	1122	1126	been
O	1127	1132	shown
O	1133	1135	to
O	1136	1138	be
O	1139	1148	effective
O	1149	1151	in
O	1152	1162	protecting
O	1163	1167	skin
O	1168	1172	from
O	1173	1182	radiation
O	1182	1183	.

O	1184	1188	Thus
O	1188	1189	,
O	1190	1194	this
O	1195	1200	pilot
O	1201	1209	provides
O	1210	1218	evidence
O	1219	1221	to
O	1222	1229	support
O	1230	1239	botanical
O	1240	1242	or
O	1243	1260	nonpharmaceutical
O	1261	1268	options
O	1269	1272	for
O	1273	1278	women
O	1279	1285	during
O	1286	1298	radiotherapy
O	1299	1302	for
O	1303	1309	breast
O	1310	1316	cancer
O	1316	1317	.
